Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296197 | 0.96 | ENPP2 (0.49) | ENPP2HDAC6 | |
| SCHEMBL30202377 | 0.96 | ENPP2 (0.49) | ENPP2HDAC6 | |
| Hydrochloric Acid SCHEMBL1921111 | 0.95 | ENPP2 (0.49) | ENPP2HDAC6 | |
| SCHEMBL1921277 | 0.85 | HDAC6 (0.51) | ENPP2HDAC6 | |
| SCHEMBL18130455 | 0.81 | ENPP2 (0.67) | ENPP2 | |
| SCHEMBL1919429 | 0.77 | ENPP2 (0.55) | ENPP2 | |
| SCHEMBL1919522 | 0.75 | ENPP2 (0.44) | ENPP2 | |
| SCHEMBL1920629 | 0.75 | CYP3A4 (0.45) | — | |
| SCHEMBL1919919 | 0.72 | ENPP2 (0.47) | ENPP2 | |
| SCHEMBL25067211 | 0.72 | ENPP2 (0.55) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299023-B2 | Neuropeptide-2 receptor (Y-2R) agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-30 | — | — | US | claimed |
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | DANHO WALEED | 2010-03-18 | — | — | US | claimed |
| US-8299023-B2 | Neuropeptide-2 receptor (Y-2R) agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299023-B2 | Neuropeptide-2 receptor (Y-2R) agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299023-B2 | Neuropeptide-2 receptor (Y-2R) agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | DANHO WALEED | 2010-03-18 | — | — | US | disclosed |
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | DANHO WALEED | 2010-03-18 | — | — | US | disclosed |
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | DANHO WALEED | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | NPY2R, NPY1R, NPY4R | ENPP2 382/4885HDAC6 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.